SF - Durring a conversation with a couple of The Zenith and RVX employees at an AGM 2 or 3 years ago before this current Phase I ZEN-3694 trial started. They were just a couple of days away from starting this current trial with another candidate when they got such compelling results from 3694 and decided to go this route. The comment made was that they had looked at numerous molecules to move forward with and what is now ZEN-3694 was the best single candidate to move forward with. As we have seen in past presentations, 3694 has been tested in animal models with 30+ existing cancer drugs and on average the combos work approximately 60% better than those drugs on their own. That kind of says it all. I look forward to hearing these current trial results whenever management feels it is best to tell us. I believe there is a very good reason we haven't heard so far and am willing to wait.

tada